↓ Skip to main content

A Phase 1/2 Trial Combining Avelumab and Trabectedin for Advanced Liposarcoma and Leiomyosarcoma

Overview of attention for article published in Clinical Cancer Research, March 2022
Altmetric Badge

About this Attention Score

  • In the top 5% of all research outputs scored by Altmetric
  • High Attention Score compared to outputs of the same age (93rd percentile)
  • High Attention Score compared to outputs of the same age and source (82nd percentile)

Mentioned by

blogs
1 blog
twitter
33 tweeters

Readers on

mendeley
2 Mendeley
You are seeing a free-to-access but limited selection of the activity Altmetric has collected about this research output. Click here to find out more.
Title
A Phase 1/2 Trial Combining Avelumab and Trabectedin for Advanced Liposarcoma and Leiomyosarcoma
Published in
Clinical Cancer Research, March 2022
DOI 10.1158/1078-0432.ccr-22-0240
Pubmed ID
Authors

Michael J. Wagner, Yuzheng Zhang, Lee D. Cranmer, Elizabeth T. Loggers, Graeme Black, Sabrina McDonnell, Shannon Maxwell, Rylee Johnson, Roxanne Moore, Pedro Hermida de Viveiros, Lauri Aicher, Kimberly S. Smythe, Qianchuan He, Robin L. Jones, Seth M. Pollack

Twitter Demographics

The data shown below were collected from the profiles of 33 tweeters who shared this research output. Click here to find out more about how the information was compiled.

Mendeley readers

The data shown below were compiled from readership statistics for 2 Mendeley readers of this research output. Click here to see the associated Mendeley record.

Geographical breakdown

Country Count As %
Unknown 2 100%

Demographic breakdown

Readers by professional status Count As %
Student > Ph. D. Student 1 50%
Unknown 1 50%
Readers by discipline Count As %
Biochemistry, Genetics and Molecular Biology 1 50%
Unknown 1 50%

Attention Score in Context

This research output has an Altmetric Attention Score of 29. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 10 June 2022.
All research outputs
#1,043,863
of 21,368,555 outputs
Outputs from Clinical Cancer Research
#721
of 12,139 outputs
Outputs of similar age
#23,077
of 337,864 outputs
Outputs of similar age from Clinical Cancer Research
#29
of 158 outputs
Altmetric has tracked 21,368,555 research outputs across all sources so far. Compared to these this one has done particularly well and is in the 95th percentile: it's in the top 5% of all research outputs ever tracked by Altmetric.
So far Altmetric has tracked 12,139 research outputs from this source. They typically receive a lot more attention than average, with a mean Attention Score of 10.2. This one has done particularly well, scoring higher than 94% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 337,864 tracked outputs that were published within six weeks on either side of this one in any source. This one has done particularly well, scoring higher than 93% of its contemporaries.
We're also able to compare this research output to 158 others from the same source and published within six weeks on either side of this one. This one has done well, scoring higher than 82% of its contemporaries.